Phase III Trials Show Tozorakimab Reduces COPD Exacerbations with Promising Safety Profile

Phase III trials indicate that tozorakimab effectively reduces COPD exacerbations and shows…

FDA Grants Breakthrough Therapy Designation to Novartis’ Ianalumab for Sjögren’s Disease

The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s…